Granulocyte-colony-stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase chronic myelogenous leukemia

Cancer

Volumn 100, Issue 12, 2004, Pages 2592-2597

  Quintas Cardama, Alfonso ^a   Kantarjian, Hagop ^a   O'Brien, Susan ^a   Garcia Manero, Guillermo ^a   Rios, Mary B ^a   Talpaz, Moshe ^a   Cortes, Jorge ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Absolute neutrophil count; Cytogenetic response; Filgrastim; Imatinib induced neutropenia; Myelosuppression

Indexed keywords

IMATINIB; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CYTOGENETICS; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; EDEMA; FEMALE; HUMAN; INFECTIOUS COMPLICATION; MALE; MUSCLE CRAMP; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; PYREXIA IDIOPATHICA; RASH; SIDE EFFECT; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

ADULT; AGED; FILGRASTIM; HUMANS; LEUKEMIA, MYELOID, CHRONIC-PHASE; MIDDLE AGED; NEUTROPENIA; PILOT PROJECTS; PIPERAZINES; PYRIMIDINES;

EID: 2642553015     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20285     Document Type: Article

References (23)

1. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2:561-566.
2. Beran M, Cao X, Estrov Z, et al. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148). Clin Cancer Res. 1998;4:1661-1672.
3. Carroll M, Ohno-Jones S, Tamura S, et al. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood. 1997;90:4947-4952.
4. Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Zigler AJ. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood. 2000;96: 925-932.
5. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002;346:645-652.
6. Kantarjian HM, Talpaz M, O'Brien S, et al. Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-α: follow-up results. Clin Cancer Res. 2002;8:2177-2187.
7. Cortes J, Giles F, O'Brien S, et al. Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-α. Blood. 2003;102:83-86.
8. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994-1004.
9. Kantarjian HM, Cortes JE, O'Brien S, et al. Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses. Blood. 2003;101:97-100.
10. Sneed TB, Kantarjian HM, Talpaz M, et al. The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase. Cancer. 2004;100:116-121.
11. Deininger MW, O'Brien SG, Ford JM, Druker BJ. Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol. 2003;21:1637-1647.
12. Marin D, Marktel S, Bua M, et al. Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa. Leukemia. 2003;17:1448-1453.
13. Lyman GH, Kuderer NM, Djulbegovic B. Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis. Am J Med. 2002;112:406-411.
14. Dale D. Current management of chemotherapy-induced neutropenia: the role of colony-stimulating factors. Semin Oncol. 2003;30(4 Suppl 13):3-9.
15. Godwin JE, Kopecky KJ, Head DR, et al. A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study (9031). Blood. 1998;91:3607-3615.
16. Moore JO, Dodge RK, Amrein PC, et al. Granulocyte-colony stimulating factor (filgrastim) accelerates granulocyte recovery after intensive postremission chemotherapy for acute myeloid leukemia with aziridinyl benzoquinone and mitoxantrone: Cancer and Leukemia Group B study 9022. Blood. 1997;89:780-788.
17. Lowenberg B, van Putten W, Theobald M, et al. Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. N Engl J Med. 2003;349:743-752.
18. Cortes J, Talpaz M, O'Brien S, et al. High-rates of major cytogenetic response in patients with newly diagnosed chronic myeloid leukemia in early chronic phase treated with imatinib at 400 mg or 800 mg daily [abstract]. Blood. 2002;100:95a.
19. Sawyers CL, Hochhaus A, Feldman E, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a Phase II study. Blood. 2002;99:3530-3539.
20. Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a Phase 2 study. Blood. 2002;99:1928-1937.
21. Kantarjian H, Talpaz M, O'Brien S, et al. Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer. 2003;97:2225-2228.
22. Kantarjian HM, Talpaz M, O'Brien S, et al. Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood. 2003;101:473-475.
23. Marin D, Marktel S, Foot N, et al. G-CSF reverses cytopenia and may increase cytogenetic responses in patients with CML treated with imatinib mesylate [abstract]. Blood. 2002; 100:782a.